A Prospective, Multicentre study to evaluate the Safety and Efficacy of Fully Absorbable, Everolimus-Eluting RENUVIATM Scaffold in patients with Coronary Artery Disease

Trial Profile

A Prospective, Multicentre study to evaluate the Safety and Efficacy of Fully Absorbable, Everolimus-Eluting RENUVIATM Scaffold in patients with Coronary Artery Disease

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 03 Jan 2018

At a glance

  • Drugs Everolimus (Primary)
  • Indications Coronary artery disease
  • Focus First in man; Therapeutic Use
  • Acronyms FAST
  • Most Recent Events

    • 03 Jan 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top